How Aliskiren Works
Aliskiren is a direct renin inhibitor that works by blocking renin at the point of activation of the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensinogen to angiotensin I, thereby reducing downstream formation of angiotensin II and ultimately lowering blood pressure 1.
Mechanism of Action
Aliskiren acts at the upstream point of the RAAS cascade, which distinguishes it from ACE inhibitors and ARBs that block the system at later stages 2, 3. Specifically:
- Inhibits renin enzymatic activity directly at its active site, preventing the first and rate-limiting step of the RAAS
- Blocks conversion of angiotensinogen to angiotensin I
- Reduces angiotensin II formation through both ACE-dependent and ACE-independent pathways
- Suppresses plasma renin activity (PRA) by up to 80% following oral administration 3
The drug is highly potent, with an in vitro IC50 of 0.6 nmol/L for human renin inhibition 3.
Pharmacological Properties
Aliskiren's unique pharmacological profile contributes to its mechanism:
- Long duration of action: Plasma half-life allows once-daily dosing, with effects persisting 2-4 weeks after discontinuation 2, 3
- Preferential kidney partitioning: The drug concentrates in renal tissue where renin is produced 2
- Sustained PRA suppression: Unlike ACE inhibitors and ARBs that increase PRA through compensatory feedback, aliskiren maintains suppression even when combined with these agents 3, 4
Blood Pressure Lowering Effect
The FDA-approved mechanism states that aliskiren helps blood vessels relax, thereby lowering blood pressure 1. Clinical studies demonstrate:
- Dose-dependent BP reduction with 150-300 mg daily dosing
- Reductions in systolic BP of 5.3-15.8 mm Hg and diastolic BP of 5.8-12.3 mm Hg 5
- Comparable efficacy to other first-line antihypertensive agents 2, 5
Important Clinical Caveat
Aliskiren should NOT be combined with ACE inhibitors or ARBs, particularly in diabetic patients, as this dual RAS blockade increases risk of stroke, kidney impairment, hyperkalemia, and hypotension 6. The ALTITUDE trial was stopped early due to these serious adverse events, leading to an FDA contraindication in 2012 6, 7. Similarly, combination therapy is contraindicated in heart failure patients 8, 9, 10.
The drug is approved for hypertension treatment in adults and pediatric patients ≥6 years weighing ≥50 kg, with the goal of reducing cardiovascular events including strokes and myocardial infarctions through blood pressure reduction 1.